GSK3B is a negative regulator of Wnt signaling pathway and inhibition of GSK3B activity, i.e. increased p-Ser9, has previously been shown to confer resistance to cisplatin in lung and ovarian cancer cells [29, 71, 72]. This evidence concerns the gene GSK3B and ovarian cancer.